Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBX 100
- Development stage
- Preclinical
- Lead developer
- Cellbricks Therapeutics
- Modality
- Cell Therapies
- Administration
- Topical
01
Overview
CBX 100 is a tissue-engineered therapeutic construct developed by Cellbricks Therapeutics for the treatment of deep complex wounds. Utilizing proprietary 3D bioprinting technology, the therapy provides a structural scaffold combined with cellular and material support to facilitate tissue restoration and repair. It is currently being evaluated in the preclinical stage for wound healing and is in the discovery phase for additional undisclosed indications. The product is part of the company's Soft Tissue Therapeutics program, which focuses on creating functional tissue constructs to fill and heal complex injuries.
Beyond the preview
Go deeper on CBX 100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBX 100.